Learn more about whether Moderna, Inc. or Roivant Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a ...

In the default model, the graph representing each individual enhancer can be arbitrarily complicated. To show how the ABC Score formula can arise from the default model, we need to impose the further ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Treatments for COPD, psoriasis, and neuroendocrine tumors, as well as a next-generation COVID-19 vaccine are under review.

Researchers from Agency for Science, Technology and Research in Singapore recently published a review article exploring how ...

Cartesian Therapeutics, Inc.’s RNAC share price has surged by 8.40%, which has investors questioning if this is right time to sell.

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Ethris, a clinical-stage biotechnology company creating RNA therapeutics and vaccines, and Lonza entered a collaboration to ...

Discover how an emerging technology called tRNA therapy could become the next big thing in genetic disease treatment.

Drug developers will now have enhanced abilities to rapidly prototype, test, iterate, and scale up their mRNA therapeutics.